Insulet ( (PODD) ) has released its Q3 earnings. Here is a breakdown of the information Insulet presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Insulet Corporation, headquartered in Massachusetts, is a leading medical device company specializing in tubeless insulin pump technology, primarily known for its Omnipod product platform, which offers an innovative alternative to traditional insulin delivery methods.
In its third-quarter 2025 earnings report, Insulet Corporation announced a significant increase in revenue, surpassing its own guidance expectations. The company reported a 29.9% revenue growth, reaching $706.3 million, driven by strong performance in its Omnipod product line both in the U.S. and internationally.
Key financial highlights include a 31.0% increase in total Omnipod revenue, with U.S. sales growing by 25.6% and international sales by 46.5%. The company achieved a gross margin of 72.2%, an improvement of 290 basis points from the previous year. Operating income rose to $117.7 million, and net income increased to $87.6 million, or $1.24 per diluted share. Strategic initiatives included integrating Omnipod 5 with Dexcom’s G7 CGM sensor in several European countries and securing reimbursement for the Omnipod 5 system in Norway.
Looking ahead, Insulet has raised its full-year revenue and margin guidance, reflecting confidence in its growth trajectory. The company anticipates continued expansion in both U.S. and international markets, with a focus on advancing diabetes care through innovative solutions and strategic partnerships.